Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + entinostat for pediatric high-risk solid and CNS tumors
ACTRN12619001768189Phase 2Active, not recruiting
- Sponsor
- Heidelberg University
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of nivolumab and entinostat in Nonhematologic neoplasms, central nervous system tumor and glioma (2 cohorts), sponsored by Heidelberg University. Started May 2020; status: active, not recruiting.
02
Drugs
nivolumabentinostat
03
Conditions
Nonhematologic neoplasmscentral nervous system tumorglioma
Beyond the preview
Go deeper on ACTRN12619001768189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001768189.